^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    B7-H3-targeted antibody-drug conjugate

    Related drugs:
    3d
    A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F) (clinicaltrials.gov)
    P1/2, N=60, Not yet recruiting, Merck Sharp & Dohme LLC
    New P1/2 trial
    |
    Keytruda (pembrolizumab) • ifinatamab deruxtecan (DS-7300)
    3d
    A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=118, Not yet recruiting, MediLink Therapeutics (Suzhou) Co., Ltd.
    New P1/2 trial
    |
    Tecentriq (atezolizumab) • YL201
    3d
    BeeHive: A Comprehensive Multiomic Biomarker Evaluation Across Two Single-arm Cohorts to Elucidate Mechanisms of Response and Resistance in Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC) (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, University Health Network, Toronto
    New P2 trial • IO biomarker
    |
    Jemperli (dostarlimab-gxly) • risvutatug rezetecan (GSK5764227)
    6d
    Tamarack: A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors (clinicaltrials.gov)
    P2, N=192, Terminated, MacroGenics | Completed --> Terminated; Business reasons
    Trial termination
    |
    PD-L1 (Programmed death ligand 1)
    |
    Xtandi (enzalutamide) • abiraterone acetate • vobramitamab duocarmazine (MGC018)
    6d
    IDeate-Lung02: A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer (clinicaltrials.gov)
    P3, N=540, Recruiting, Daiichi Sankyo | Active, not recruiting --> Recruiting
    Enrollment open
    |
    topotecan • Zepzelca (lurbinectedin) • ifinatamab deruxtecan (DS-7300) • Calsed (amrubicin)
    10d
    A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002) (clinicaltrials.gov)
    P1/2, N=242, Recruiting, Merck Sharp & Dohme LLC | Trial completion date: Aug 2029 --> Feb 2030
    Trial completion date
    |
    Imfinzi (durvalumab) • ifinatamab deruxtecan (DS-7300) • gocatamig (MK-6070)
    13d
    A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001) (clinicaltrials.gov)
    P1/2, N=232, Active, not recruiting, Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    DLL3 (Delta Like Canonical Notch Ligand 3)
    |
    Tecentriq (atezolizumab) • ifinatamab deruxtecan (DS-7300) • gocatamig (MK-6070)
    15d
    Phase I/II clinical study of SYS6043 combined with PD-1/PD-L1 inhibitor ± chemotherapy in the treatment of advanced solid tumor participants (ChiCTR2500112838)
    P1/2, N=622, Not yet recruiting, Sun Yat-sen University Cancer Center; Sun Yat-sen University Cancer Center
    New P1/2 trial
    |
    cisplatin • carboplatin • gemcitabine • Tevimbra (tislelizumab-jsgr) • pemetrexed • etoposide IV • Hetronifly (serplulimab) • Enshuxing (enlonstobart)
    20d
    A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer (clinicaltrials.gov)
    P3, N=736, Not yet recruiting, BioNTech SE
    New P3 trial
    |
    docetaxel • prednisone • BNT324
    29d
    Evaluation of the Effect of Itraconazole on the Pharmacokinetics of HS-20093 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=18, Recruiting, Hansoh BioMedical R&D Company | Not yet recruiting --> Recruiting | Trial primary completion date: Dec 2025 --> Jul 2026
    Enrollment open • Trial primary completion date
    |
    itraconazole • risvutatug rezetecan (GSK5764227)
    1m
    The investigational anti-B7-H3 antibody-drug conjugate vobramitamab duocarmazine exerts anti-tumor activity in vitro and in vivo in pediatric sarcoma preclinical models. (PubMed, Cell Death Dis)
    Repeated vobra duo doses ameliorated this outcome, reverting rhabdomyosarcorma to rhabdomyoma tumor, by increasing Desmin and Myogenin/Myf-4 differentiation markers expression, and reducing both Ki-67 and CD133. In conclusion, the in vitro and in vivo anti-tumor effects towards pSC highlight the need to extend the investigation to patient-derived preclinical models, to pave the way for clinical translation.
    Preclinical • Journal
    |
    CD276 (CD276 Molecule) • CASP3 (Caspase 3) • EIF4EBP1 (Eukaryotic translation initiation factor 4E binding protein 1)
    |
    vobramitamab duocarmazine (MGC018)
    1m
    A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=84, Recruiting, GlaxoSmithKline | Phase classification: P1/2 --> P1 | Not yet recruiting --> Recruiting
    Enrollment open • Phase classification
    |
    Avastin (bevacizumab) • 5-fluorouracil • Xtandi (enzalutamide) • leucovorin calcium • risvutatug rezetecan (GSK5764227)